Therefore, our study aimed to develop a DL-based model to predict recurrence risk in patients with HER2-low breast cancer and to compare the performance of the MRI-alone prediction model, clinicopathologic-alone prediction model, with combined MRI features and clinicopathologic variables. Here, ERBB2 is linked to breast cancer.